

HOMCY CHARLES J
Form 4
October 05, 2017

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
HOMCY CHARLES J

2. Issuer Name and Ticker or Trading Symbol
Global Blood Therapeutics, Inc. [GBT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2017

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	10/03/2017		S	0 <u>(1)</u> D <u>(1)</u> \$ 0	0 <u>(2)</u>	I	See Footnote <u>(3)</u>
Common Stock	10/03/2017		S	0 <u>(4)</u> D <u>(4)</u> \$ 0	0 <u>(5)</u>	I	See Footnote <u>(6)</u>
Common Stock	10/04/2017		S	0 <u>(7)</u> D <u>(7)</u> \$ 0	0 <u>(8)</u>	I	See Footnote <u>(3)</u>

Edgar Filing: HOMCY CHARLES J - Form 4

Common Stock	10/04/2017	S	0 ⁽⁹⁾	D	\$ 0 ₍₉₎	0 ⁽¹⁰⁾	I	See Footnote <u>(6)</u>
Common Stock	10/04/2017	S	0 ⁽¹¹⁾	D	\$ 0 ₍₁₁₎	0 ⁽¹²⁾	I	See Footnote <u>(3)</u>
Common Stock	10/04/2017	S	0 ⁽¹³⁾	D	\$ 0 ₍₁₃₎	0 ⁽¹⁴⁾	I	See Footnote <u>(6)</u>
Common Stock						137,728	D	
Common Stock						1,600	I	By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HOMCY CHARLES J C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO, CA 94080		X		

Signatures

/s/ Charles
Homcy

10/05/2017

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On October 3, 2017, Third Rock Ventures II, L.P. ("TRV II") sold 62,373 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of \$30.171. These shares were sold in multiple transactions at prices ranging from \$29.75 to \$30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (7), (9), (11) and (13) to this Form 4.

(2) After the transaction referenced in footnote (1), TRV II owned 1,273,032 shares.

The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

On October 3, 2017, Third Rock Ventures III, L.P. ("TRV III") sold 72,463 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of \$30.171. These shares were sold in multiple transactions at prices ranging from \$29.75 to \$30.55, inclusive.

(5) After the transaction referenced in footnote (4), TRV III owned 213,250 shares.

The reporting person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The reporting person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.

(7) On October 4, 2017, TRV II sold 53,652 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of \$30.38. These shares were sold in multiple transactions at prices ranging from \$29.60 to \$30.60, inclusive.

(8) After the transaction referenced in footnote (7), TRV II owned 1,219,380 shares.

(9) On October 4, 2017, TRV III sold 62,332 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of \$30.38. These shares were sold in multiple transactions at prices ranging from \$29.60 to \$30.60, inclusive.

(10) After the transaction referenced in footnote (9), TRV III owned 150,918 shares.

(11) On October 4, 2017, TRV II sold 129,902 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of \$30.86. These shares were sold in multiple transactions at prices ranging from \$30.65 to \$31.15, inclusive.

(12) After the transaction referenced in footnote (11), TRV II owned 1,089,478 shares.

(13) On October 4, 2017, TRV III sold 150,918 shares of Common Stock of the Issuer. The shares were sold at a weighted average price of \$30.86. These shares were sold in multiple transactions at prices ranging from \$30.65 to \$31.15, inclusive.

(14) After the transaction referenced in footnote (13), TRV III owned no shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.